论文部分内容阅读
目的观察二甲双胍对糖耐量减低(IGT)合并冠心病患者行冠状动脉介入术后的影响。方法将IGT合并冠状动脉病变且接受冠状动脉介入术治疗的125例患者分为两组。治疗组64例,在常规治疗的基础上加用二甲双胍进行干预;对照组61例,仅予常规治疗。观察术后1年的心血管事件及支架内再狭窄的发生情况。结果术后1年110例患者获得随访,治疗组56例,对照组54例。治疗组心血管事件和支架内再狭窄发生率分别为14％(8／56例)和18％(10／56例),均明显低于对照组的22％(12／54例)和26％(14／54例,P值均<0．01)。结论在IGT合并冠心病并行冠状动脉介入术的患者中,应用二甲双胍进行干预,可以降低心血管事件及冠状动脉支架内再狭窄发生率。
Objective To investigate the effect of metformin on patients with impaired glucose tolerance (IGT) and coronary heart disease (CHD) after coronary intervention. Methods One hundred and twenty-five patients with IGT with coronary artery disease undergoing coronary artery intervention were divided into two groups. Treatment group of 64 cases, on the basis of conventional therapy plus metformin intervention; control group of 61 patients, only routine treatment. One year postoperative cardiovascular events and in-stent restenosis were observed. Results One hundred and one patients were followed up one year after operation. There were 56 cases in the treatment group and 54 cases in the control group. The incidence of cardiovascular events and in-stent restenosis were 14% (8/56) and 18% (10/56) in the treatment group, respectively, which were significantly lower than those in the control group (22/54 cases) and 26% (14/54 cases, P <0.01). Conclusions Metformin can reduce the incidence of cardiovascular events and coronary in-stent restenosis in patients with IGT complicated with coronary artery disease undergoing coronary artery intervention.